Concurrent Investment Advisors’s Protalix BioTherapeutics PLX Stock Holding History

Concurrent Investment Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$349K	Buy	+126,314	New	+$314K	﹤0.01%	1784

Other funds holding PLX

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

OGF

Orin Green Financial San Diego, California $267M AUM 12.91% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Investment Research & Advisory Group Atlanta, Georgia $337M AUM 19.8% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Concurrent Investment Advisors's PLX Position: Q3 2026 in Review

Concurrent Investment Advisors opened a new position in Protalix BioTherapeutics (PLX) in Q3 2026: 126,314 shares worth $349K. The stake represents ﹤0.01% of the portfolio and ranks #1784 among its holdings.

11 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Concurrent Investment Advisors held 126,314 shares of Protalix BioTherapeutics worth $349K as of Q3 2026.
Protalix BioTherapeutics was a new Concurrent Investment Advisors position in Q3 2026.
Protalix BioTherapeutics made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q3 2026, its #1784 holding.
11 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Concurrent Investment Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.